Cytosorbents (CTSO) AI Stock Analysis

• Market Cap: $49.66M
• Dividend Yield: N/A
• Average Volume (3M): 76.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: -7.81%
• EPS Growth: 65.39%
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.03
• Shares Outstanding: 62,761,806
• 10 Day Avg. Volume: 63,287
• 30 Day Avg. Volume: 76,802
• PEG Ratio: 0.06
• Price to Book (P/B): 4.46
• Price to Sales (P/S): 1.39
• P/FCF Ratio: -3.37
• Enterprise Value/Market Cap: 2.08
• Enterprise Value/Revenue: 3.08
• Enterprise Value/Gross Profit: 4.24
• Enterprise Value/Ebitda: -10.44
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.50 ▼(-30.56% Downside)

Cytosorbents' overall stock score is primarily impacted by its challenging financial performance, characterized by high leverage and negative cash flows. Technical indicators suggest bearish momentum, and valuation metrics are weak due to ongoing losses. While the earnings call highlighted some positive developments, regulatory hurdles and increased expenses pose risks.

Positive Factors

Product Sales Growth

The 9% YoY growth in product sales indicates strong demand and market acceptance, which supports long-term revenue potential and business expansion.

German Market Expansion

Successful reorganization in Germany, leading to 22% growth, suggests effective market strategies and potential for further international expansion.

Strong Gross Margin

A strong gross margin of 71% reflects efficient cost management and operational effectiveness, supporting long-term profitability potential.

Negative Factors

Regulatory Challenges

Regulatory setbacks for DrugSorb ATR could delay market entry and revenue generation, impacting long-term growth prospects.

High Operating Expenses

Rising operating expenses, up 3%, strain profitability and could hinder efforts to achieve breakeven, affecting financial stability.

Negative Cash Flow

Negative cash flows pose liquidity challenges, limiting the company's ability to invest in growth and manage debt, affecting long-term viability.

Cytosorbents Business Overview & Revenue Model

Company Description

Cytosorbents Corporation (CTSO) is a medical technology company focused on developing and commercializing innovative products for critical care and cardiac surgery. The company specializes in blood purification technology, particularly through its flagship product, CytoSorb, which is designed to remove harmful substances from the bloodstream during severe inflammatory conditions. Cytosorbents operates primarily in the healthcare sector, targeting hospitals and medical facilities that require advanced treatment options for patients experiencing life-threatening conditions.

How the Company Makes Money

Cytosorbents generates revenue primarily through the sale of its CytoSorb devices and related products to hospitals and healthcare providers. The company employs a direct sales model in certain markets, while also working with distributors and partners to expand its reach. Key revenue streams include the sale of disposable CytoSorb cartridges, which are used in conjunction with the device for blood purification during critical care treatments. The company has established significant partnerships with medical institutions and research organizations, which not only enhance its product visibility but also facilitate clinical studies that can lead to broader adoption of its technologies. Additionally, Cytosorbents may explore opportunities for reimbursement from healthcare payers, further contributing to its earnings potential.

Cytosorbents Financial Statement Overview

Summary

Cytosorbents faces significant financial challenges, with consistent losses and high leverage. Despite strong gross profit margins, profitability is hindered by high operating expenses and negative cash flows, posing risks to financial stability.

Income Statement

Cytosorbents has shown a slight improvement in revenue growth with a TTM growth rate of 2.37%. However, the company continues to face significant profitability challenges, as indicated by negative net profit and EBIT margins. The gross profit margin remains strong at 72.57%, suggesting efficient cost management at the production level, but overall profitability is hindered by high operating expenses.

Balance Sheet

The company's balance sheet reflects high leverage with a debt-to-equity ratio of 2.34, indicating a reliance on debt financing. The return on equity is negative, highlighting ongoing losses. The equity ratio stands at 24.14%, suggesting a moderate level of equity financing relative to total assets, but the high debt levels pose a risk to financial stability.

Cash Flow

Cytosorbents is experiencing negative operating and free cash flows, with a declining free cash flow growth rate of -24.67% in the TTM period. The operating cash flow to net income ratio is close to 1, indicating that cash flow generation is in line with net losses, but the overall cash flow situation remains weak, posing liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	33.48M	35.59M	31.08M	29.36M	40.11M	39.45M
Gross Profit	24.30M	25.13M	21.95M	15.40M	29.06M	28.40M
EBITDA	-9.87M	-19.26M	-27.88M	-32.77M	-21.62M	-9.71M
Net Income	-9.75M	-20.72M	-29.25M	-32.81M	-24.56M	-7.84M
Balance Sheet
Total Assets	47.99M	47.37M	53.26M	63.23M	89.52M	89.95M
Cash, Cash Equivalents and Short-Term Investments	10.20M	3.28M	14.13M	22.14M	52.14M	71.42M
Total Debt	27.06M	26.89M	18.31M	18.25M	13.82M	1.03M
Total Liabilities	36.40M	36.26M	29.99M	27.86M	26.94M	10.73M
Stockholders Equity	11.59M	11.11M	23.28M	35.38M	62.58M	79.22M
Cash Flow
Free Cash Flow	-10.29M	-14.71M	-22.59M	-34.69M	-18.29M	-7.29M
Operating Cash Flow	-9.78M	-14.43M	-21.66M	-28.23M	-14.01M	-5.61M
Investing Cash Flow	-601.55K	-669.43K	-936.24K	-6.46M	-4.28M	-1.68M
Financing Cash Flow	6.90M	9.33M	14.47M	4.96M	715.20K	66.35M

Cytosorbents Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTSO, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.82, below the 50-day MA of 0.89, and below the 200-day MA of 0.99, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 29.89 is Positive, neither overbought nor oversold. The STOCH value of 6.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTSO.

Cytosorbents Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	64 Neutral	$92.75M	11.98	4.92%	―	1.43%	-20.12%
SRTS	64 Neutral	$69.05M	―	-5.71%	―	-13.79%	-132.21%
XTNT	52 Neutral	$103.88M	-20.78	-9.80%	―	15.16%	-39.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HYPR	47 Neutral	$96.28M	-1.97	-77.26%	―	-9.59%	8.78%
NSPR	45 Neutral	$88.66M	-2.52	-87.61%	―	14.04%	-0.65%
CTSO	41 Neutral	$49.66M	-4.34	-68.84%	―	-7.81%	65.39%

Cytosorbents Corporate Events

Cytosorbents Corp’s Latest Study Update: A Game Changer in Critical Care?

Study Overview: The CytOSorb TreatMent Of Critically Ill PatientS Registry is an international observational study aimed at creating a comprehensive data repository to monitor the use of the CytoSorb device in real-world critical care settings. This registry seeks to enhance the quality of patient care by providing a scientifically-based resource for measuring and improving treatment outcomes in conditions such as septic shock, acute respiratory distress syndrome, and more.

CytoSorbents’ STAR Registry: A Closer Look at the Latest Clinical Study Update

The Safe and Timely Antithrombotic Removal (STAR) Registry is an international observational study conducted by CytoSorbents Corp. Its primary aim is to document real-world clinical use and outcomes of the CytoSorb device, specifically for removing antithrombotic agents in acute hospital settings. This study is significant as it addresses critical conditions such as surgical and postoperative hemorrhage, providing insights into the device’s effectiveness and safety.

Cytosorbents Faces Nasdaq Non-Compliance Notice

On October 2, 2025, CytoSorbents Corporation received a notice from Nasdaq for non-compliance with the Minimum Bid Price Requirement, as its stock price remained below $1.00 for 30 consecutive business days. The company has until March 31, 2026, to regain compliance by ensuring its stock price meets or exceeds $1.00 for at least 10 consecutive days. Failure to comply could lead to an additional compliance period if an acceptable plan is presented to Nasdaq. The company is actively monitoring its stock price and exploring options to meet the requirement.

The most recent analyst rating on (CTSO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.

Cytosorbents Corp Q2 2025 Earnings Call Highlights

Cytosorbents Corp’s recent earnings call reflected a balanced sentiment, highlighting positive growth in product sales and strategic advancements in the German market, while also addressing significant regulatory hurdles with the DrugSorb ATR product. Despite an increase in operational costs, the company remains optimistic about its appeal processes and potential future growth.

CytoSorbents Reports Positive Q2 2025 Financial Results

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through its innovative blood purification technologies. The company specializes in removing toxic substances from blood, offering solutions for critical illnesses such as sepsis and septic shock.